Today’s Watch List: Viking Therapeutics, Inc. (NASDAQ:VKTX), GenVec, Inc. (NASDAQ:GNVC), Roka Bioscience, Inc. (NASDAQ:ROKA), Aratana Therapeutics, Inc. (NASDAQ:PETX), Zynga Inc (NASDAQ:ZNGA)

Viking Therapeutics, Inc. (NASDAQ:VKTX) belongs to Healthcare sector. Its weekly performance is 2.47%. On last trading day company shares ended up $7.05. Viking Therapeutics, Inc. (NASDAQ:VKTX) distance from 50-day simple moving average (SMA50) is -12.37%. Viking Therapeutics, Inc. (NASDAQ: VKTX), announced that it has submitted an investigational new drug (IND) application to the Food and Drug Administration (FDA) to initiate clinical development of VK5211 in patients with acute hip fracture.

GenVec, Inc. (NASDAQ:GNVC) shares moved up 10.27% in last trading session and ended the day at $2.47. GNVC return on assets is -21.10%. GenVec, Inc. (NASDAQ:GNVC) quarterly performance is -14.24%. Zacks reaffirmed their hold rating on shares of GenVec (NASDAQ:GNVC) in a report released on Friday.

On 14 July, Roka Bioscience, Inc. (NASDAQ:ROKA) shares advanced 3.65% and was closed at $3.41. Roka Bioscience, Inc. (NASDAQ:ROKA) year to date (YTD) performance is -22.68%. Roka Bioscience, Inc. (NASDAQ:ROKA) announced that its Atlas Listeria Environmental Detection Assay (Atlas LE Assay) has received AOAC Performance Tested MethodsSM certification from the AOAC Research Institute (AOAC-RI). The assay is approved for the detection of Listeria spp. (including Listeria monocytogenes, Listeria innocua, Listeria welshimeri, Listeria ivanovii, Listeria seeligeri, and Listeria grayi) from environmental surfaces (stainless steel grade 316, plastic (PVC), and sealed concrete) after a 24 hour enrichment.

Aratana Therapeutics, Inc. (NASDAQ:PETX) ended the last trading day at $16.77. Company weekly volatility is calculated as 4.96% and price to cash ratio as 6.70. Aratana Therapeutics, Inc. (NASDAQ:PETX) showed a weekly performance of 13.08%.Aratana Therapeutics (NASDAQ: PETX) announced positive results from its pivotal field effectiveness study of AT-003, the company’s innovative drug for treating post-surgical pain in dogs. AT-003 is an extended-release bupivacaine liposome injectable suspension licensed from Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX).

Zynga Inc (NASDAQ:ZNGA) shares moved up 3.00% in last trading session and ended the day at $2.75. ZNGA Gross Margin is 69.20% and its return on assets is -9.00%. Zynga Inc (NASDAQ:ZNGA) quarterly performance is 12.70%. On July 1, 2015 Zynga Inc. (NASDAQ:ZNGA) entered into the First Amendment to its Amended and Restated Revolving Credit Agreement dated as of the Effective Date, among the Company, the lenders party thereto and Morgan Stanley Senior Funding, Inc., as Administrative Agent. The First Amendment amended the Company’s Amended and Restated Revolving Credit Agreement dated as of June 20, 2013, among the Company, the Lenders party thereto and the Administrative Agent.

Leave a Reply

Your email address will not be published. Required fields are marked *